178 related articles for article (PubMed ID: 37352275)
21. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
[TBL] [Abstract][Full Text] [Related]
22. 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
Alhallak K; de la Puente P; Jeske A; Sun J; Muz B; Rettig MP; Sahin I; Weisberg EL; Griffin JD; Reagan JL; DiPersio JF; Azab AK
Leuk Lymphoma; 2021 Oct; 62(10):2457-2465. PubMed ID: 33993837
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells.
Tian C; Zheng G; Zhuang H; Li X; Hu D; Zhu L; Wang T; You MJ; Zhang Y
J Cell Physiol; 2017 Jun; 232(6):1387-1395. PubMed ID: 27696394
[TBL] [Abstract][Full Text] [Related]
24. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
25. Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications.
Crompot E; Van Damme M; Pieters K; Vermeersch M; Perez-Morga D; Mineur P; Maerevoet M; Meuleman N; Bron D; Lagneaux L; Stamatopoulos B
Haematologica; 2017 Sep; 102(9):1594-1604. PubMed ID: 28596280
[TBL] [Abstract][Full Text] [Related]
26. Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma.
Plander M; Ugocsai P; Seegers S; Orsó E; Reichle A; Schmitz G; Hofstädter F; Brockhoff G
Ann Hematol; 2011 Dec; 90(12):1381-90. PubMed ID: 21465189
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia.
von Heydebrand F; Fuchs M; Kunz M; Voelkl S; Kremer AN; Oostendorp RAJ; Wilke J; Leitges M; Egle A; Mackensen A; Lutzny-Geier G
Stem Cells; 2021 Jun; 39(6):819-830. PubMed ID: 33539629
[TBL] [Abstract][Full Text] [Related]
29. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract][Full Text] [Related]
30. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Purroy N; Abrisqueta P; Carabia J; Carpio C; Calpe E; Palacio C; Castellví J; Crespo M; Bosch F
Leukemia; 2014 Oct; 28(10):1993-2004. PubMed ID: 24618734
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
[TBL] [Abstract][Full Text] [Related]
32. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
Davids MS; Deng J; Wiestner A; Lannutti BJ; Wang L; Wu CJ; Wilson WH; Brown JR; Letai A
Blood; 2012 Oct; 120(17):3501-9. PubMed ID: 22955911
[TBL] [Abstract][Full Text] [Related]
33. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.
Kurtova AV; Balakrishnan K; Chen R; Ding W; Schnabl S; Quiroga MP; Sivina M; Wierda WG; Estrov Z; Keating MJ; Shehata M; Jäger U; Gandhi V; Kay NE; Plunkett W; Burger JA
Blood; 2009 Nov; 114(20):4441-50. PubMed ID: 19762485
[TBL] [Abstract][Full Text] [Related]
34. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.
Vangapandu HV; Ayres ML; Bristow CA; Wierda WG; Keating MJ; Balakrishnan K; Stellrecht CM; Gandhi V
Neoplasia; 2017 Oct; 19(10):762-771. PubMed ID: 28863345
[TBL] [Abstract][Full Text] [Related]
35. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
Aleskog A; Larsson R; Höglund M; Kristensen J; Nygren P; Lindhagen E
Anticancer Drugs; 2005 Mar; 16(3):277-83. PubMed ID: 15711179
[TBL] [Abstract][Full Text] [Related]
36. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
[TBL] [Abstract][Full Text] [Related]
37. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.
Valsecchi R; Coltella N; Belloni D; Ponente M; Ten Hacken E; Scielzo C; Scarfò L; Bertilaccio MT; Brambilla P; Lenti E; Martinelli Boneschi F; Brendolan A; Ferrero E; Ferrarini M; Ghia P; Tonon G; Ponzoni M; Caligaris-Cappio F; Bernardi R
Blood; 2016 Apr; 127(16):1987-97. PubMed ID: 26825709
[TBL] [Abstract][Full Text] [Related]
38. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.
Steele AJ; Prentice AG; Cwynarski K; Hoffbrand AV; Hart SM; Lowdell MW; Samuel ER; Wickremasinghe RG
Blood; 2010 Nov; 116(22):4569-77. PubMed ID: 20716767
[TBL] [Abstract][Full Text] [Related]
39. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
Zhang W; Trachootham D; Liu J; Chen G; Pelicano H; Garcia-Prieto C; Lu W; Burger JA; Croce CM; Plunkett W; Keating MJ; Huang P
Nat Cell Biol; 2012 Feb; 14(3):276-86. PubMed ID: 22344033
[TBL] [Abstract][Full Text] [Related]
40. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
